CVE-2025-61940
Mirion Biodose/nmis vulnerability
- Published2 Dec 2025
Description
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
CVSS 3.1 breakdown
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:LAffected products
Remediation
Related CVEs
Recent high-severity vulnerabilities sharing a weakness type.
Frequently asked
Is CVE-2025-61940 being actively exploited?
CVE-2025-61940 is not in the CISA KEV catalog. Its EPSS exploit probability is 0.32%.
How severe is CVE-2025-61940?
CVE-2025-61940 has a CVSS 3.1 base score of 8.3, rated high. EPSS estimates a 0.32% probability of exploitation.
Which products are affected by CVE-2025-61940?
Affected products include Mirion Biodose/nmis.
How do I fix CVE-2025-61940?
Upgrade affected software to a fixed version, for example Mirion Biodose/nmis 23.0 or later, then confirm no affected versions remain in your inventory.
How Secuno handles this
Secuno correlates vulnerabilities like CVE-2025-61940 against the real software inventory on every managed device, as each hourly inventory arrives. Rather than a static severity, each match is scored in context: exploit availability, EPSS, the asset's exposure, and business criticality decide where it lands in the queue. If an affected version is present anywhere across your portfolio, it surfaces automatically with a prioritised remediation path.
Data from the NVD, CISA KEV catalog and FIRST EPSS. CVSS 3.1 base score shown where available.